Antitrust Settlements	9 Months Ended
Jun. 30, 2026
Commitments and Contingencies Disclosure [Abstract]
Antitrust Settlements	Antitrust Settlements Numerous lawsuits have been filed against certain brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. These lawsuits are generally brought as class actions. The Company has not been named as a plaintiff in these lawsuits but has been a member of the direct purchasers’ class (i.e., those purchasers who purchase directly from these pharmaceutical manufacturers). None of the lawsuits has gone to trial but some have settled in the past with the Company receiving proceeds from the settlement funds. The Company recognized gains related to these lawsuits of $5.5 million and $9.5 million in the three months ended June 30, 2026 and 2025, respectively. The Company recognized gains related to these lawsuits of $34.2 million and $231.0 million in the nine months ended June 30, 2026 and 2025, respectively. These gains, which are net of attorneys’ fees and estimated payments due to other parties, were recorded as reductions to cost of goods sold in the Company’s Consolidated Statements of Operations.

Antitrust Settlements

9 Months Ended

Jun. 30, 2026

Commitments and Contingencies Disclosure [Abstract]

Numerous lawsuits have been filed against certain brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. These lawsuits are generally brought as class actions. The Company has not been named as a plaintiff in these lawsuits but has been a member of the direct purchasers’ class (i.e., those purchasers who purchase directly from these pharmaceutical manufacturers). None of the lawsuits has gone to trial but some have settled in the past with the Company receiving proceeds from the settlement funds. The Company recognized gains related to these lawsuits of $5.5 million and $9.5 million in the three months ended June 30, 2026 and 2025, respectively. The Company recognized gains related to these lawsuits of $34.2 million and $231.0 million in the nine months ended June 30, 2026 and 2025, respectively. These gains, which are net of attorneys’ fees and estimated payments due to other parties, were recorded as reductions to cost of goods sold in the Company’s Consolidated Statements of Operations.